10-Q: Avalo Therapeutics Reports Q2 2024 Results, Bolstered by $115.6 Million Private Placement

Avalo Therapeutics reports a net loss of $22.8 million for the first half of 2024, but is well-funded after a $115.6 million private placement and anticipates cash runway into 2027.

Summary

• Avalo Therapeutics reported a net loss of $22.8 million for the six months ended June 30, 2024.
• The company's cash and cash equivalents stood at $93.4 million as of June 30, 2024.
• A significant private placement in the first quarter of 2024 brought in $115.6 million in gross proceeds, with net proceeds of $108.1 million after deducting transaction costs.
• The company expects its current cash to fund operations into 2027.
• Avalo acquired AVTX-009 through a merger with AlmataBio, incurring $27.6 million in acquired in-process research and development expenses.
• There was no product revenue for the six months ended June 30, 2024, due to the expiration of the Millipred license agreement.
• Research and development expenses totaled $6.7 million for the six months ended June 30, 2024, a decrease compared to $10.7 million in the same period of 2023.
• The company recognized a $112.0 million gain from the change in fair value of warrant liability, offset by a $79.3 million loss on the initial warrant fair value exceeding private placement proceeds.
• Avalo's general and administrative expenses increased to $7.7 million for the six months ended June 30, 2024, compared to $5.1 million in the same period of 2023.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. The company has secured significant funding and is advancing its pipeline, which is positive. However, it also reports a net loss and faces several risks, including potential delisting and the need for further capital. The overall sentiment is cautiously optimistic.

Positives

• The $115.6 million private placement significantly strengthened Avalo's financial position.
• The acquisition of AVTX-009 adds a promising lead asset to the company's pipeline.
• The company's cash runway extends into 2027, providing financial stability.
• The activation of the IND for AVTX-009 and the planned commencement of the Phase 2 LOTUS Trial are significant milestones.
• The appointments of a new Chief Legal Officer and Chief Medical Officer strengthen the management team.

Negatives

• Avalo reported a net loss of $22.8 million for the first half of 2024.
• There was no product revenue for the six months ended June 30, 2024, due to the expiration of the Millipred license agreement.
• The company incurred $27.6 million in acquired in-process research and development expenses related to the AlmataBio merger.
• General and administrative expenses increased by $2.6 million for the six months ended June 30, 2024.
• The company recognized a $79.3 million loss on the initial warrant fair value exceeding private placement proceeds.

Risks

• The company has a history of operating and cash losses.
• Future financing may dilute existing stockholders' ownership.
• The company may have to relinquish valuable rights to its technologies if it raises additional funds through collaborations or licensing arrangements.
• The company's success depends on obtaining and maintaining intellectual property rights.
• The company's patents for AVTX-009 and AVTX-002 expire in 2026, 2027, or 2028.
• The company's stock is subject to delisting if it does not meet Nasdaq's continued listing requirements.
• The company needs stockholder approval for the conversion of preferred stock and exercise of warrants, which may not be obtained.
• The company is subject to a mandatory panel monitor by Nasdaq for a period of one year from January 30, 2024.
• The company has a 180-day extension until November 18, 2024 to regain compliance with the Nasdaq Listing Rule regarding minimum stockholders equity.

Future Outlook

Avalo expects its current cash to fund operations into 2027 and plans to commence the Phase 2 LOTUS Trial in the second half of 2024. The company may seek additional funding through various means, including equity sales, out-licensing, and strategic alliances.

Management Comments

• Management's primary evaluation of the success of the Company is the ability to progress its pipeline forward toward commercialization or opportunistically out-licensing rights to indications or geographies.
• We believe the ability to achieve the anticipated milestone as presented in the following chart represents our most immediate evaluation point as to the progress of our goal to move the pipeline forward.

Industry Context

The company is operating in the competitive biotechnology sector, focused on developing treatments for immune dysregulation. The acquisition of AVTX-009 and the commencement of the Phase 2 trial are significant steps in advancing its pipeline. The company's financial position is strengthened by the recent private placement, but it still faces risks common to the industry, including regulatory hurdles and the need for further funding.

Comparison to Industry Standards

• Avalo's cash position of $93.4 million is relatively strong for a clinical-stage biotech company, especially after the recent private placement. This compares favorably to other companies in the sector that often face funding challenges.
• The company's R&D expenses of $6.7 million for the first half of 2024 are lower than some peers, reflecting the stage of its pipeline and the conclusion of the quisovalimab PEAK trial. Companies like Xencor (XNCR) and IGM Biosciences (IGMS), which are also developing antibody-based therapeutics, often have higher R&D spending due to more advanced clinical programs.
• The $27.6 million in acquired IPR&D expense is a significant one-time cost related to the AlmataBio acquisition. This is a common occurrence in the biotech industry when companies acquire assets or technologies.
• The $112 million gain from the change in fair value of warrant liability is unusual and is a result of the specific terms of the private placement and the volatility of the company's stock price. This is not a typical metric for comparison with other biotech companies.
• Avalo's focus on AVTX-009 for hidradenitis suppurativa is a strategic move into a specific therapeutic area. Companies like Incyte (INCY) and AbbVie (ABBV) have also been active in this space, but Avalo's approach with an anti-IL-1 monoclonal antibody is differentiated.

Management Changes

Legal Proceedings

• The Company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business.
• The Company currently does not believe that the resolution of such matters will have a material adverse effect on its financial position or results of operations except as otherwise disclosed in this report.

Related Party Transactions

• In July 2019, Aevi entered into a royalty agreement with certain investors, including LeoGroup Private Investment Access, LLC on behalf of Garry Neil, the Company's Chief Executive Officer and Chairman of the Board, and Mike Cola, the Company's former Chief Executive Officer.
• On June 9, 2021, the Company assigned its rights, title, interest, and obligations under an in-license covering its non-core asset, AVTX-406, to ES, a wholly owned subsidiary of Armistice, who was a significant stockholder of the Company at the time of the transaction and whose chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalo's Board until August 8, 2022.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from future equity offerings.
• Employees will be impacted by the company's financial performance and strategic decisions.
• Customers and suppliers will be impacted by the company's ability to develop and commercialize its products.
• Creditors will be impacted by the company's ability to repay its debts.

Next Steps

• Avalo plans to enroll the first patient in its Phase 2 LOTUS Trial in the second half of 2024.
• The company will seek stockholder approval for the conversion of preferred stock and exercise of warrants at its annual meeting on August 13, 2024.
• The company will continue to monitor the milestones and royalties at each reporting period.
• The company will continue to monitor the second milestone related to the Aevi Merger each reporting period.

Key Dates

Keywords

AVTX-009, hidradenitis suppurativa, private placement, clinical trial, biotechnology, monoclonal antibody, immune dysregulation, warrant liability, preferred stock, LOTUS Trial